Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- PEPG
- Price
- 5.63
- Stock movement up
- +0.22 (4.07%)
- Company name
- PepGen Ltd
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 387.05M
- Ent value
- 271.19M
- Price/Sales
- 259.42
- Price/Book
- 2.37
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- 171.33%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
PEPG does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 259.42 |
| Price to Book | 2.37 |
| EV to Sales | 181.77 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 68.75M |
| EPS (TTM) | -2.86 |
| FCF per share (TTM) | -2.62 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 1.49M |
| Gross profit (TTM) | -1.44M |
| Operating income (TTM) | -98.25M |
| Net income (TTM) | -93.56M |
| EPS (TTM) | -2.86 |
| EPS (1y forward) | -1.28 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -96.58% |
| Operating margin (TTM) | -6585.25% |
| Profit margin (TTM) | -6270.58% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 142.78M |
| Net receivables | 0.00 |
| Total current assets | 166.21M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 25.51M |
| Total assets | 190.06M |
| Accounts payable | 766.00K |
| Short/Current long term debt | 17.44M |
| Total current liabilities | 12.64M |
| Total liabilities | 26.92M |
| Shareholder's equity | 163.14M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -85.27M |
| Capital expenditures (TTM) | 493.00K |
| Free cash flow (TTM) | -85.76M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -57.35% |
| Return on Assets | -49.23% |
| Return on Invested Capital | -56.26% |
| Cash Return on Invested Capital | -51.57% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 5.43 |
| Daily high | 5.70 |
| Daily low | 5.36 |
| Daily Volume | 491K |
| All-time high | 18.55 |
| 1y analyst estimate | 10.00 |
| Beta | 1.91 |
| EPS (TTM) | -2.86 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 19 Mar 2026 |
Downside potential
Loading...
Downside potential data
| PEPG | S&P500 | |
| Current price drop from All-time high | -69.65% | -0.89% |
| Highest price drop | -94.61% | -19.00% |
| Date of highest drop | 8 Apr 2025 | 8 Apr 2025 |
| Avg drop from high | -81.99% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 322 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
387.05M
Marketcap category
Small-cap
Description
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. Its lead product candidates comprise PGN-EDO51, an EDO peptide which is Phase 2 clinical trial to treat duchenne muscular dystrophy (DMD) patients that are amenable to an exon 51-skipping approach; PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and PGN-EDO53, which is in preclinical trial to treat duchenne muscular dystrophy. The company was founded in 2018 and is based in Boston, Massachusetts.
Employees
57
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page